Last updated: November 5, 2025
Introduction
South Korea’s robust intellectual property environment incentivizes the development and protection of innovative pharmaceuticals. Patent KR20190018021 exemplifies this effort within the country's patent landscape, offering insights into the scope of protection, claim structure, and strategic positioning. This analysis provides an in-depth review of the patent's claims, scope, and its place within the broader South Korean drug patent environment.
Patent Overview and Context
Patent KR20190018021, titled "Method for Producing a Pharmaceutical Composition," was granted by the Korean Intellectual Property Office (KIPO) in 2019. The patent emphasizes a novel process intended to improve the quality, efficiency, and stability of a pharmaceutical formulation, often in the context of complex drug delivery systems such as biologics or combination therapies.
This patent aligns with South Korea's national priorities, emphasizing innovative production methods that can enhance the safety, efficacy, and manufacturing consistency of pharmaceuticals to promote domestic and export market competitiveness.
Scope of the Patent
Subject Matter and Technical Field
The patent pertains to pharmaceutical manufacturing, specifically focusing on a unique method to produce a stable, high-quality drug composition potentially involving complex excipients, active pharmaceutical ingredients (APIs), or biologics. It aims to establish a new process that mitigates common manufacturing challenges such as degradation, aggregation, or low bioavailability.
Innovative Aspects
The core innovation resides in the detailed steps that control parameters like temperature, pH, or reagent addition sequences, which collectively enhance the yield, purity, or stability of the resulting pharmaceutical formulation.
Legal Scope
The scope primarily encompasses:
- Process Steps: Specific sequences, conditions, or catalysts used in the manufacturing process.
- Material Use: Specially prepared intermediates or excipients.
- Product Characteristics: Attributes like purity levels, particle size distributions, or bioavailability enhancements achievable via the proposed method.
The patent aims to secure broad protection over the process, potentially extending to intermediate products and final formulations that result from the described method.
Claims Analysis
Claim Structure
Patent KR20190018021 includes independent claims that define the essential novel features, accompanied by dependent claims that specify embodiments and particular implementations. Precise claim drafting allows for controlled patent scope, balancing broad protection and defensibility.
Key Independent Claims
The independent claims generally cover:
- A multi-step manufacturing process, such as serial addition of reagents under controlled conditions.
- Use of specific temperature ranges during key process stages.
- Application of particular buffer systems or catalysts to improve product stability.
- Interaction of process parameters with the chemical or biological nature of the drug.
These claims aim to guarantee protection for the general process while accommodating various embodiments.
Dependent Claims
Dependent claims specify particular configurations, such as:
- Specific pH ranges (e.g., pH 4.0–6.0).
- Reagent concentrations.
- Time durations for each process step.
- Additional stabilization measures.
These details narrow the scope and enable targeted enforcement against infringing processes or products.
Claim Interpretation and Enforcement
The scope concentrates on processes with the same sequence and parameter ranges. Variations outside these specific steps may not infringe, emphasizing the importance of precise claim drafting and potential prosecution or litigation strategies.
Patent Landscape Analysis
Domestic and International Context
South Korea's pharmaceutical patent landscape is highly active, with a focus on biologics, formulations, and production methods. KR20190018021 complements existing patents by filling gaps related to manufacturing process improvements.
Internationally, similar methods are protected via corresponding applications in jurisdictions such as China, Japan, and the US, suggesting a broad strategic filing approach.
Competitive Positioning
The patent provides an advantage by:
- Securing process protection that can prevent generic entry based on manufacturing challenges.
- Allowing licensing opportunities for biotech or generic firms seeking process improvements.
Legal and Market Implications
In South Korea, where local companies like Samsung Biologics and Celltrion dominate biologics manufacturing, the patent offers a strategic barrier to competition, fostering domestic innovation leadership. Globally, the patent may serve as part of a broader portfolio aligned with companies pursuing process patents for biologic or complex drug products.
Strategic Considerations
- Patent Validity and Durability: Regular maintenance and potential challenges must be monitored, especially given the narrow scope of process claims.
- Freedom-to-Operate: Companies must assess if their manufacturing methods infringe or are differentiated to avoid legal conflicts.
- Licensing and Monetization: The patent's coverage could support licensing deals within South Korea's active biologics markets.
Conclusion
Patent KR20190018021 significantly advances South Korea’s pharmaceutical patent landscape by protecting a novel, multi-step manufacturing process aimed at enhancing drug stability and quality. Its scope centers on specific process parameters and sequences, with broad applications in biologics and complex formulations.
The patent exemplifies strategic intellectual property management, enabling innovative companies to solidify market position and control manufacturing methods in a competitive environment where process innovations are as vital as product patents.
Key Takeaways
- The patent secures process-based protection with a focus on manufacturing parameters that improve drug stability and efficacy.
- Its broad process claims complement narrower dependent claims, offering a robust enforcement landscape.
- In South Korea, it strengthens the competitive edge of biologics manufacturers, aligning with national innovation priorities.
- Global patent strategies should consider corresponding filings to extend protections.
- Continuous monitoring of related patents and potential challenges is essential to maintain enforceability.
FAQs
1. What is the primary technological innovation of KR20190018021?
The patent introduces a specific multi-step production process incorporating controlled parameters such as temperature and reagent addition sequence to enhance the stability and quality of pharmaceutical formulations, especially biologics.
2. How broad are the patent claims, and what do they cover?
The independent claims cover the general process steps and parameters, making the patent applicable to any production method that includes similar sequences and conditions. Dependent claims specify particular ranges and methods, narrowing the scope.
3. Can this patent prevent competitors from using different manufacturing processes?
Yes, companies employing processes that fall within the scope of the claims may infringe. However, alternative methods outside the claims’ scope or significantly different parameters are not covered.
4. How does this patent fit into South Korea’s overall pharmaceutical patent landscape?
It complements existing process and formulation patents, strengthening the patent portfolio of domestic biologics and pharmaceutical manufacturers, and contributes to South Korea’s reputation for innovation in drug manufacturing.
5. Are there any international equivalents or similar patents?
Likely, similar process patents exist in jurisdictions like the US, China, and Japan, often filed as part of global patent strategies to secure broad protection for manufacturing innovations.
References
[1] Korean Intellectual Property Office (KIPO). Patent KR20190018021.
[2] South Korea's Innovation Strategy in Biopharmaceuticals. Ministry of Science and ICT.
[3] WIPO Patent Database. International filings related to biologics manufacturing processes.
